Wagenlehner F M E, Naber K G
Urologic Clinic, Hospital St. Elisabeth Straubing, St. Elisabeth Str. 23, D-94315 Straubing, Germany.
Curr Urol Rep. 2004 Aug;5(4):309-16. doi: 10.1007/s11934-004-0058-y.
Chronic bacterial prostatitis is the most frequent cause for recurrent urinary tract infection in young and middle-aged men. The selection of an appropriate antimicrobial agent that has optimal pharmacokinetics for urine and prostatic secretion and tissue is important in both entities. Fluoroquinolones possess several pharmacologic characteristics that favor them for treatment of urinary tract infection and prostatitis. The pharmacokinetics of fluoroquinolones and the theoretical background of drug penetration into the prostate are outlined. Analyzing the concentrations of various fluoroquinolones in urine, prostatic and seminal fluid, and in prostatic tissue, it becomes obvious that the fluoroquinolones differ in plasma concentrations and in their concentrations at these sites. Nevertheless, overall, the concentrations at the site of infection of most of the fluoroquinolones should be sufficient for the treatment of chronic bacterial prostatitis and vesiculitis and recurrent urinary tract infection in men caused by susceptible pathogens.
慢性细菌性前列腺炎是中青年男性反复发生尿路感染的最常见原因。选择一种对尿液、前列腺分泌物和组织具有最佳药代动力学的合适抗菌药物，对这两种情况都很重要。氟喹诺酮类药物具有多种药理学特性，有利于治疗尿路感染和前列腺炎。本文概述了氟喹诺酮类药物的药代动力学以及药物渗透入前列腺的理论背景。通过分析各种氟喹诺酮类药物在尿液、前列腺液和精液以及前列腺组织中的浓度，可以明显看出氟喹诺酮类药物在血浆浓度以及这些部位的浓度方面存在差异。然而，总体而言，大多数氟喹诺酮类药物在感染部位的浓度应足以治疗慢性细菌性前列腺炎、精囊炎以及由易感病原体引起的男性反复尿路感染。
